Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | NT5E | P21589 | 10/20 | 0.36 |
| ▸ | ADK | P55263 | 4/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23765562 | 1.00 | ADORA1 (0.37) | ADORA1NT5EADKP2RY2ADORA3 | |
| SCHEMBL23765402 | 1.00 | ADORA1 (0.37) | ADORA1NT5EADKP2RY2ADORA3 | |
| SCHEMBL23765632 | 1.00 | ADORA1 (0.37) | ADORA1NT5EADKP2RY2ADORA3 | |
| SCHEMBL23765621 | 1.00 | ADORA1 (0.37) | ADORA1NT5EADKP2RY2ADORA3 | |
| SCHEMBL23765603 | 1.00 | ADORA1 (0.37) | ADORA1NT5EADKP2RY2ADORA3 | |
| SCHEMBL23765596 | 0.96 | ADORA1 (0.39) | ADORA1NT5EADORA3ADORA2ATAS1R3 | |
| SCHEMBL23765636 | 0.94 | ADK (0.35) | ADORA1NT5EADKP2RY2 | |
| SCHEMBL23752729 | 0.94 | ADK (0.35) | ADORA1NT5EADKP2RY2 | |
| SCHEMBL23765474 | 0.94 | ADK (0.35) | ADORA1NT5EADKP2RY2 | |
| SCHEMBL23765467 | 0.94 | ADK (0.35) | ADORA1NT5EADKP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | ADORA1 35/4885NT5E 2/4885ADK 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.